Izraelis - anglų - Ministry of Health

neopharm scientific ltd - pomalidomide - hard capsule - pomalidomide 4 mg - pomalidomide - imnovid in combination with dexamethasone is indicated in the treatment of adult patients with relapsed and refractory multiple myeloma who have received at least two prior treatment regimens, including both lenalidomide and bortezomib, and have demonstrated disease progression on the last therapy.imnovid in combination with bortezomib and dexamethasone is indicated in the treatment of adult patients with multiple myeloma who have received at least one prior treatment regimen including lenalidomide

Izraelis - anglų - Ministry of Health

neopharm scientific ltd - pomalidomide - hard capsule - pomalidomide 4 mg - pomalidomide - imnovid in combination with dexamethasone is indicated in the treatment of adult patients with relapsed and refractory multiple myeloma who have received at least two prior treatment regimens, including both lenalidomide and bortezomib, and have demonstrated disease progression on the last therapy.imnovid in combination with bortezomib and dexamethasone is indicated in the treatment of adult patients with multiple myeloma who have received at least one prior treatment regimen including lenalidomide

Izraelis - anglų - Ministry of Health

neopharm scientific ltd - pomalidomide - hard capsule - pomalidomide 4 mg - pomalidomide - imnovid in combination with dexamethasone is indicated in the treatment of adult patients with relapsed and refractory multiple myeloma who have received at least two prior treatment regimens, including both lenalidomide and bortezomib, and have demonstrated disease progression on the last therapy.imnovid in combination with bortezomib and dexamethasone is indicated in the treatment of adult patients with multiple myeloma who have received at least one prior treatment regimen including lenalidomide

Kanada - anglų - Health Canada

bristol-myers squibb canada - pomalidomide - capsule - 3mg - pomalidomide 3mg - antineoplastic agents

Saudo Arabija - anglų - SFDA (Saudi Food and Drug Authority)- الهيئة العامة للغذاء والدواء

sudair pharma company, saudi arabia - pomalidomide - capsule, hard - 3 mg

Saudo Arabija - anglų - SFDA (Saudi Food and Drug Authority)- الهيئة العامة للغذاء والدواء

sudair pharma company, saudi arabia - pomalidomide - capsule, hard - 3 mg

Australija - anglų - Department of Health (Therapeutic Goods Administration)

juno pharmaceuticals pty ltd - pomalidomide, quantity: 2 mg - capsule, hard - excipient ingredients: croscarmellose sodium; mannitol; sodium stearylfumarate; pregelatinised starch; titanium dioxide; indigo carmine; purified water; iron oxide yellow; erythrosine; gelatin; propylene glycol; butan-1-ol; isopropyl alcohol; shellac; ethanol absolute; ammonia; potassium hydroxide - pomalidomide, in combination with bortezomib and dexamethasone, is indicated for the treatment of patients with relapsed or refractory multiple myeloma who have received at least one prior treatment regimen including lenalidomide.,pomalidomide, in combination with dexamethasone, is indicated for the treatment of patients with relapsed and refractory multiple myeloma who have received at least two prior treatment regimens, including both lenalidomide and bortezomib, and have demonstrated disease progression on the last therapy.

Australija - anglų - Department of Health (Therapeutic Goods Administration)

juno pharmaceuticals pty ltd - pomalidomide, quantity: 1 mg - capsule, hard - excipient ingredients: pregelatinised starch; croscarmellose sodium; mannitol; sodium stearylfumarate; titanium dioxide; indigo carmine; purified water; iron oxide yellow; gelatin; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; shellac; strong ammonia solution; iron oxide black; potassium hydroxide; ethanol absolute; ammonia - pomalidomide, in combination with bortezomib and dexamethasone, is indicated for the treatment of patients with relapsed or refractory multiple myeloma who have received at least one prior treatment regimen including lenalidomide.,pomalidomide, in combination with dexamethasone, is indicated for the treatment of patients with relapsed and refractory multiple myeloma who have received at least two prior treatment regimens, including both lenalidomide and bortezomib, and have demonstrated disease progression on the last therapy.

Australija - anglų - Department of Health (Therapeutic Goods Administration)

juno pharmaceuticals pty ltd - pomalidomide, quantity: 4 mg - capsule, hard - excipient ingredients: pregelatinised starch; mannitol; sodium stearylfumarate; croscarmellose sodium; titanium dioxide; indigo carmine; purified water; gelatin; propylene glycol; butan-1-ol; isopropyl alcohol; shellac; ethanol absolute; ammonia; potassium hydroxide - pomalidomide, in combination with bortezomib and dexamethasone, is indicated for the treatment of patients with relapsed or refractory multiple myeloma who have received at least one prior treatment regimen including lenalidomide.,pomalidomide, in combination with dexamethasone, is indicated for the treatment of patients with relapsed and refractory multiple myeloma who have received at least two prior treatment regimens, including both lenalidomide and bortezomib, and have demonstrated disease progression on the last therapy.

Malaizija - anglų - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

dr. reddy`s laboratories malaysia sdn. bhd. - pomalidomide -